{"generic":"Ritonavir","drugs":["Norvir","Ritonavir"],"mono":[{"id":"923544-s-0","title":"Generic Names","mono":"Ritonavir"},{"id":"923544-s-1","title":"Dosing and Indications","sub":[{"id":"923544-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>HIV infection:<\/b> Ritonavir is recommended only as a pharmacokinetic enhancer of other protease inhibitors or integrase strand inhibitors when in low doses (100 mg to 400 mg\/day in 1 to 2 divided doses, depending on the antiretroviral regimen used) (guideline dosing)<\/li><li><b>HIV infection:<\/b> (Sole protease inhibitor) initial, 300 mg ORALLY twice daily, increase by 100 mg twice daily ORALLY every 2 to 3 days up to maintenance dose of 600 mg ORALLY twice daily; MAX 600 mg ORALLY twice daily (manufacturer dosing)<\/li><\/ul>"},{"id":"923544-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>do not administer oral solution to neonates before postmenstrual age of 44 weeks<\/li><li>when oral solution is used in infants and young children 1 to 6 months of age, it is critical to ensure correct dose calculation and administration, and to account for any alcohol and propylene glycol in concomitant medication<\/li><li><b>HIV infection:<\/b> Ritonavir is recommended only as a pharmacokinetic enhancer of other protease inhibitors or integrase strand inhibitors when used in low doses depending on the antiretroviral regimen used<\/li><li><b>HIV infection:<\/b> (Sole protease inhibitor) children older than 1 month; initial, 250 mg\/m(2) ORALLY twice daily, increase by 50 mg\/m(2) ORALLY twice daily every 2 to 3 days, up to maintenance dose of 350 to 400 mg\/m(2) ORALLY twice daily; MAX 600 mg ORALLY twice daily<\/li><\/ul>"},{"id":"923544-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>hepatic impairment, mild or moderate (Child-Pugh class A or B):<\/b> no dose adjustment needed<\/li><li><b>hepatic impairment, severe (Child-Pugh class C):<\/b> use is not recommended<\/li><li>concomitant protease inhibitor (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir); reduced ritonavir dose is recommended<\/li><\/ul>"},{"id":"923544-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>HIV infection<br\/>"}]},{"id":"923544-s-2","title":"Black Box Warning","mono":"<b>Oral (Capsule, Liquid Filled; Solution; Tablet)<\/b><br\/>Coadministration of ritonavir with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious or life-threatening adverse events due to possible effects of ritonavir on the hepatic metabolism of certain drugs. Review medications taken by patients prior to prescribing ritonavir or when prescribing other medications to patients already taking ritonavir.<br\/>"},{"id":"923544-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923544-s-3-9","title":"Contraindications","mono":"<ul><li>Concomitant use of alfuzosin hydrochloride, amiodarone, flecainide, propafenone, quinidine, voriconazole (with ritonavir doses of 400 mg every 12 hours or greater), dihydroergotamine, ergotamine, methylergonovine, cisapride, St. John's wort (Hypericum perforatum), lovastatin, simvastatin, pimozide, sildenafil (for the treatment of pulmonary arterial hypertension), oral midazolam, or triazolam<\/li><li>Hypersensitivity (eg, toxic epidermal necrolysis or Stevens-Johnson syndrome) to ritonavir or to any component of the product<\/li><\/ul>"},{"id":"923544-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- Cardiac conduction abnormalities (eg, prolongation of the PR interval, second- and third-degree atrioventricular block) may occur; increased risk in patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, cardiomyopathies, or concomitant use of PR-interval prolonging drugs; monitoring recommended<\/li><li>Dermatologic:<\/li><li>-- Allergic skin reactions, some severe (eg, toxic epidermal necrolysis, Stevens-Johnson syndrome), have been reported; discontinue use if severe reactions occur<\/li><li>Endocrine and Metabolic:<\/li><li>-- Lipid disorders, significant increases in total cholesterol and triglycerides, have been reported; monitoring recommended<\/li><li>-- Hyperglycemia, diabetic ketoacidosis, and new onset or exacerbation of preexisting diabetes mellitus may occur<\/li><li>Gastrointestinal:<\/li><li>-- Pancreatitis, including fatalities, has been reported, with an increased risk in advanced HIV disease; discontinue with diagnosis<\/li><li>Hematologic:<\/li><li>-- In patients with hemophilia type A or B, increased bleeding (eg, skin hematomas, hemarthrosis) may occur<\/li><li>Hepatic:<\/li><li>-- Hepatotoxicity (eg, transaminase elevations over 5 times the ULN, clinical hepatitis, jaundice), sometimes fatal, has been reported; risk factors include concomitant use of multiple medications, underlying hepatitis B or C, preexisting liver disease, liver enzyme abnormalities, or hepatitis; monitoring recommended<\/li><li>-- Severe hepatic impairment; use not recommended<\/li><li>Immunologic:<\/li><li>-- Allergic or hypersensitivity reactions, some severe (eg, angioedema, anaphylaxis) have been reported; discontinue use if severe reactions occur<\/li><li>-- Indolent or residual opportunistic infections; inflammatory response (immune reconstitution syndrome) may occur<\/li><li>-- Autoimmune disorders, including Graves disease, polymyositis, and Guillain-Barr  syndrome, have been reported in the setting of immune reconstitution; may occur many months after initiation of therapy<\/li><li>-- Cross-resistance has been reported between protease inhibitors; increased risk with continued treatment following loss of viral suppression<\/li><li>Other:<\/li><li>-- Preterm neonates (postmenstrual age less than 44 weeks) are at increased risk of propylene glycol-associated adverse events, including life-threatening cardiac toxicity (eg, complete atrioventricular block, bradycardia, and cardiomyopathy), lactic acidosis, acute renal failure, CNS depression, and respiratory complications leading to death; use of oral solution not recommended in preterm neonates in immediate postnatal period unless benefit outweighs risk, in which case close monitoring is recommended<\/li><li>Concomitant Use:<\/li><li>-- Concomitant use with saquinavir and rifampin not recommended; consider alternative antimycobacterial agents (eg, rifabutin)<\/li><li>-- Concomitant use with meperidine (long-term use or dose increase) not recommended<\/li><li>-- Concomitant use with rivaroxaban should be avoided<\/li><li>-- Concomitant use with high doses (greater than 200 mg\/day) of ketoconazole or itraconazole not recommended<\/li><li>-- Concomitant use of voriconazole with ritonavir 100 mg should be avoided unless benefit justifies risk<\/li><li>-- Concomitant use with colchicine in patients with renal or hepatic impairment not recommended<\/li><li>-- Concomitant use with simeprevir not recommended<\/li><li>-- Concomitant use with inhaled or intranasal steroids (eg, fluticasone, budesonide) metabolized by CYP3A not recommended unless benefit outweighs risk of systemic corticosteroid side effects<\/li><li>-- Concomitant use with salmeterol not recommended<\/li><li>-- Concomitant use with avanafil not recommended<\/li><li>-- Concomitant use with systemic glucocorticoids (eg, dexamethasone, prednisone) metabolized by CYP3A not recommended unless benefit outweighs risk of systemic corticosteroid side effects<\/li><li>-- Concomitant use with rifampin, rifapentine, or rivaroxaban not recommended<\/li><\/ul>"},{"id":"923544-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"923544-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"923544-s-4","title":"Drug Interactions","sub":[{"id":"923544-s-4-13","title":"Contraindicated","mono":"<ul><li>Alfuzosin (theoretical)<\/li><li>Amifampridine (theoretical)<\/li><li>Amiodarone (probable)<\/li><li>Astemizole (probable)<\/li><li>Bepridil (theoretical)<\/li><li>Carbamazepine (established)<\/li><li>Cisapride (probable)<\/li><li>Colchicine (established)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dihydroergotamine (probable)<\/li><li>Dronedarone (theoretical)<\/li><li>Efavirenz (established)<\/li><li>Eletriptan (theoretical)<\/li><li>Encainide (theoretical)<\/li><li>Eplerenone (theoretical)<\/li><li>Ergoloid Mesylates (probable)<\/li><li>Ergonovine (probable)<\/li><li>Ergotamine (probable)<\/li><li>Eszopiclone (theoretical)<\/li><li>Ethinyl Estradiol (theoretical)<\/li><li>Everolimus (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Ibrutinib (theoretical)<\/li><li>Irinotecan (theoretical)<\/li><li>Isavuconazonium Sulfate (probable)<\/li><li>Ivabradine (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Lovastatin (theoretical)<\/li><li>Lurasidone (probable)<\/li><li>Maraviroc (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Methylergonovine (probable)<\/li><li>Methysergide (probable)<\/li><li>Midazolam (theoretical)<\/li><li>Naloxegol (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nimodipine (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pimozide (probable)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (probable)<\/li><li>Ranolazine (theoretical)<\/li><li>Riociguat (theoretical)<\/li><li>Romidepsin (probable)<\/li><li>Sildenafil (established)<\/li><li>Silodosin (probable)<\/li><li>Simvastatin (probable)<\/li><li>Sparfloxacin (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Suvorexant (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Triazolam (probable)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Vorapaxar (theoretical)<\/li><li>Voriconazole (probable)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"923544-s-4-14","title":"Major","mono":"<ul><li>Acarbose (theoretical)<\/li><li>Ado-Trastuzumab Emtansine (theoretical)<\/li><li>Afatinib (theoretical)<\/li><li>Albiglutide (theoretical)<\/li><li>Alogliptin (theoretical)<\/li><li>Alprazolam (probable)<\/li><li>Amlodipine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Aprepitant (probable)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Avanafil (probable)<\/li><li>Axitinib (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Boceprevir (established)<\/li><li>Bosentan (probable)<\/li><li>Bosutinib (theoretical)<\/li><li>Brentuximab Vedotin (theoretical)<\/li><li>Bromocriptine (theoretical)<\/li><li>Budesonide (theoretical)<\/li><li>Bupropion (probable)<\/li><li>Buserelin (theoretical)<\/li><li>Cabazitaxel (established)<\/li><li>Cabozantinib (theoretical)<\/li><li>Canagliflozin (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Chlorpropamide (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Clarithromycin (established)<\/li><li>Cobicistat (probable)<\/li><li>Cyclophosphamide (established)<\/li><li>Cyclosporine (established)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Daclatasvir (theoretical)<\/li><li>Dapagliflozin (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (probable)<\/li><li>Deslorelin (theoretical)<\/li><li>Dexamethasone (theoretical)<\/li><li>Digoxin (probable)<\/li><li>Docetaxel (probable)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Dulaglutide (theoretical)<\/li><li>Empagliflozin (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Etravirine (probable)<\/li><li>Exenatide (theoretical)<\/li><li>Fluoxetine (established)<\/li><li>Fluticasone (theoretical)<\/li><li>Furosemide (established)<\/li><li>Fusidic Acid (probable)<\/li><li>Garlic (probable)<\/li><li>Glimepiride (theoretical)<\/li><li>Glipizide (theoretical)<\/li><li>Glyburide (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Idelalisib (theoretical)<\/li><li>Ifosfamide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Insulin Aspart, Recombinant (theoretical)<\/li><li>Insulin Degludec (theoretical)<\/li><li>Insulin Detemir (theoretical)<\/li><li>Insulin Glargine, Recombinant (theoretical)<\/li><li>Insulin Glulisine (theoretical)<\/li><li>Insulin Human Inhaled (theoretical)<\/li><li>Insulin Human Isophane (NPH) (theoretical)<\/li><li>Insulin Human Regular (theoretical)<\/li><li>Insulin Lispro, Recombinant (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Ixabepilone (theoretical)<\/li><li>Ketoconazole (established)<\/li><li>Lacosamide (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Liraglutide (theoretical)<\/li><li>Lixisenatide (theoretical)<\/li><li>Macitentan (theoretical)<\/li><li>Metformin (theoretical)<\/li><li>Methylenedioxymethamphetamine (probable)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Miglitol (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nintedanib (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Omeprazole (established)<\/li><li>Ondansetron (theoretical)<\/li><li>Oxycodone (theoretical)<\/li><li>Palbociclib (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Ponatinib (theoretical)<\/li><li>Pramlintide (theoretical)<\/li><li>Pravastatin (established)<\/li><li>Prednisolone (theoretical)<\/li><li>Prednisone (theoretical)<\/li><li>Quinine (established)<\/li><li>Regorafenib (theoretical)<\/li><li>Retapamulin (theoretical)<\/li><li>Rifabutin (established)<\/li><li>Rifampin (probable)<\/li><li>Rifapentine (theoretical)<\/li><li>Rivaroxaban (established)<\/li><li>Rosiglitazone (theoretical)<\/li><li>Rosuvastatin (established)<\/li><li>Ruxolitinib (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Sertraline (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Simeprevir (established)<\/li><li>Sitagliptin (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Tadalafil (probable)<\/li><li>Tamoxifen (theoretical)<\/li><li>Tamsulosin (theoretical)<\/li><li>Temsirolimus (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Tolazamide (theoretical)<\/li><li>Tolbutamide (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Triamcinolone (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Venlafaxine (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Vildagliptin (theoretical)<\/li><li>Vinblastine (probable)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><\/ul>"},{"id":"923544-s-4-15","title":"Moderate","mono":"<ul><li>Acenocoumarol (probable)<\/li><li>Amitriptyline (probable)<\/li><li>Amprenavir (probable)<\/li><li>Cerivastatin (probable)<\/li><li>Clonazepam (probable)<\/li><li>Dalfopristin (probable)<\/li><li>Delavirdine (established)<\/li><li>Desipramine (probable)<\/li><li>Desogestrel (probable)<\/li><li>Didanosine (probable)<\/li><li>Dienogest (probable)<\/li><li>Diltiazem (probable)<\/li><li>Disopyramide (probable)<\/li><li>Drospirenone (probable)<\/li><li>Dutasteride (probable)<\/li><li>Estradiol Cypionate (probable)<\/li><li>Estradiol Valerate (probable)<\/li><li>Ethynodiol Diacetate (probable)<\/li><li>Etonogestrel (probable)<\/li><li>Fosamprenavir (probable)<\/li><li>Imipramine (probable)<\/li><li>Indinavir (probable)<\/li><li>Itraconazole (probable)<\/li><li>Lamotrigine (established)<\/li><li>Levonorgestrel (probable)<\/li><li>Levothyroxine (probable)<\/li><li>Medroxyprogesterone Acetate (probable)<\/li><li>Meperidine (probable)<\/li><li>Mestranol (probable)<\/li><li>Methadone (probable)<\/li><li>Methamphetamine (probable)<\/li><li>Mexiletine (probable)<\/li><li>Nefazodone (probable)<\/li><li>Norelgestromin (probable)<\/li><li>Norethindrone (probable)<\/li><li>Norgestimate (probable)<\/li><li>Norgestrel (probable)<\/li><li>Paroxetine (probable)<\/li><li>Prasugrel (established)<\/li><li>Quinupristin (probable)<\/li><li>Risperidone (probable)<\/li><li>Tenofovir Disoproxil Fumarate (probable)<\/li><li>Theophylline (probable)<\/li><li>Trazodone (probable)<\/li><li>Valproic Acid (probable)<\/li><li>Verapamil (probable)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},{"id":"923544-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Edema, Including peripheral edema (adult, 6.3%)<\/li><li><b>Dermatologic:<\/b>Flushing (adult, 13.2%), Pruritus of skin (adult, 12.2%), Rash (adult, 27.1%; pediatric, 2% or greater)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain, Upper and lower (adult, 26.4%), Diarrhea (adult, 67.9%; pediatric, 2% or greater), Nausea (adult, 57.4%), Taste sense altered (adult, 16.2%), Vomiting (adult, 31.9%; pediatric, 2% or greater)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia, Including back pain (adult, 18.6%)<\/li><li><b>Neurologic:<\/b>Asthenia (adult, 46.2%), Dizziness (adult, 15.6%), Paresthesia, Including oral paresthesia (adult, 50.7%), Peripheral neuropathy (adult, 10.1%)<\/li><li><b>Respiratory:<\/b>Cough (adult, 21.7%), Pain in throat (adult, 15.9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Atrioventricular block, Prolonged PR interval, Right bundle branch block, Syncope (adult, 3.3%)<\/li><li><b>Dermatologic:<\/b>Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Endocrine metabolic:<\/b>Diabetes mellitus, Hyperglycemia, Lipodystrophy (2.9%), Serum cholesterol raised, Greater than 240 mg\/dL (antiretroviral-naive adults, 30.7% to 44.8%; advanced adult patients, 36.5%; protease inhibitor-naive adults, 65.2%), Serum triglycerides raised, Fasting level greater than 1500 mg\/dL (antiretroviral-naive adults, 1.3% to 1.5%; advanced adult patients, 9.9%; protease inhibitor-naive adults, 0%)<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis<\/li><li><b>Hematologic:<\/b>Bleeding, Increased in patients with hemophilia, Neutropenia, Grade 3 or 4 (pediatric, 9%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised, Greater than 215 units\/L (antiretroviral-naive adults, 5.3% to 7.8%; advanced adult patients, 8.5%; protease inhibitor-naive adults, 9.2%), AST\/SGOT level raised, Greater than 180 units\/L (antiretroviral-naive adults, 5.3% to 9.5%; advanced adult patients, 6.4%; protease inhibitor-naive adults, 7.8%), Hepatitis, Including increased transaminase levels (adult, 8.7%), Hepatotoxicity<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction (adult, 8.2%; pediatric, 2% or greater), Immune reconstitution syndrome<\/li><\/ul>"},{"id":"923544-s-6","title":"Drug Name Info","sub":{"0":{"id":"923544-s-6-17","title":"US Trade Names","mono":"Norvir<br\/>"},"2":{"id":"923544-s-6-19","title":"Class","mono":"<ul><li>Antiretroviral Agent<\/li><li>Protease Inhibitor<\/li><\/ul>"},"3":{"id":"923544-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"923544-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},{"id":"923544-s-7","title":"Mechanism Of Action","mono":"Ritonavir is a protease inhibitor. It inhibits both human immunodeficiency virus proteases (HIV-1 and HIV-2), which leaves these enzymes incapable of processing the gag-pol polyprotein precursor. This leads to the production of noninfectious immature HIV particles.<br\/>"},{"id":"923544-s-8","title":"Pharmacokinetics","sub":[{"id":"923544-s-8-23","title":"Absorption","mono":"<ul><li>Tmax: 2 hr (fasting) and 4 hr (non-fasting)<\/li><li>Effect of food: (soft gelatin capsule), 15% increased absorption<\/li><li>Effect of food: (oral solution) no effect on extent or rate of absorption<\/li><\/ul>"},{"id":"923544-s-8-24","title":"Distribution","mono":"<ul><li>Vd: adults, 0.41 +\/- 0.25 L\/kg<\/li><li>Protein binding: 98 to 99%<\/li><\/ul>"},{"id":"923544-s-8-25","title":"Metabolism","mono":"<ul><li> Hepatic; CYP3A (major) and CYP2D6<\/li><li>Active metabolite: Isopropylthiazole, similar antiviral activity to ritonavir but has low plasma concentrations<\/li><\/ul>"},{"id":"923544-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 86.4%, 33.8% unchanged<\/li><li>Renal: adults, 11.3%, 3.5% unchanged<\/li><li>Dialyzable: no (hemodialysis)<\/li><\/ul>"},{"id":"923544-s-8-27","title":"Elimination Half Life","mono":"3 to 5 hr.<br\/>"}]},{"id":"923544-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>take with meals<\/li><li>(solution) mix with 8 ounces chocolate milk, Ensure(R), or Advera(R) within 1 hour of dose to improve taste<\/li><li>(solution) infants and young children; ensure correct dose calculation and administration, and account for alcohol and propylene glycol in concomitant medications in order to avoid potential toxicity<\/li><li>(solution) shake well before each use and administer dose with a calibrated dosing syringe<\/li><li>(tablet) swallow whole; do not chew, break, or crush<\/li><li>concomitant didanosine: dosing of didanosine and ritonavir should be separated by 2 hours<\/li><\/ul>"},{"id":"923544-s-10","title":"Monitoring","mono":"<ul><li>(adults and adolescents) viral load: at baseline and with modification of antiretroviral (ARV) treatment, at 2 to 8 weeks; then every 4 to 8 weeks until values are below the limit of detection (less than 200 copies\/mL), then every 3 to 4 months; monitoring may be extended to every 6 months for patients who are immunologically stable, adherent, and with suppressed viral loads for more than 2 years<\/li><li>(adults and adolescents) CD4 cell counts: at baseline and with modification of ARV treatment, then every 3 to 6 months during at least the first 2 years of treatment and if the CD4 counts are less than 300 cell\/mm(3) or viremia develops; after 2 years monitoring may be extended to every 12 months for patients who are clinically stable with suppressed viral loads<\/li><li>(adults and adolescents) hepatitis B screening: baseline and with modification of ARV treatment; may repeat screening if hepatitis B surface antigen or antibody are negative at baseline.<\/li><li>(pediatrics) viral load: at baseline and with modification of ARV treatment, within 2 to 4 weeks, then every 3 to 4 months thereafter<\/li><li>(pediatrics) CD4 count\/percentage: at baseline and with modification of ARV treatment, then every 3 to 4 months; less frequent monitoring for children adherent to treatment who have remained clinically stable and have maintained viral suppression and CD4 counts above the threshold for opportunistic infection for more than 2 to 3 years<\/li><li>(pediatrics) clinical history, physical exam, and evaluation of adherence: at baseline at 1 to 2 weeks and 2 to 4 weeks following initiation or modification of ARV treatment, then every 3 to 4 months thereafter<\/li><li>(all patients) clinical response; more closely in patients with moderate hepatic impairment<\/li><li>(all patients) CPK and uric acid levels; at baseline and periodically during therapy<\/li><li>(adults and adolescents) ALT, AST, and total bilirubin; at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 3 to 6 months, or as clinically indicated; consider increased ALT\/AST monitoring in patients with preexisting liver disease, liver enzyme abnormalities, or underlying hepatitis B or C, particularly during the first 3 month of therapy<\/li><li>(adults and adolescents) basic chemistry including serum sodium, potassium, bicarbonate, chloride, BUN, and creatinine; at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 3 to 6 months<\/li><li>(adults and adolescents) CBC with a differential; at baseline and with modification of ARV treatment, then every 3 to 6 months<\/li><li>(adults and adolescents) fasting blood glucose or HbA1c; at baseline and with modification of ARV treatment, then every 3 to 6 months in patients with abnormal values or every 12 months in patients with normal values<\/li><li> (adults and adolescents) fasting lipid profile; at baseline and with modification of ARV treatment, at 4 to 8 weeks, then every 6 to 12 months or as clinically indicated<\/li><li>(adults and adolescents) urinalysis; at baseline or modification of therapy, then annually<\/li><li>(pediatrics) basic chemistry including creatinine, electrolytes, and glucose; at baseline and with modification of ARV treatment, at 2 to 4 weeks after treatment initiation, then every 3 to 4 months thereafter<\/li><li>(pediatrics) CBC with differential; at baseline and with modification of ARV treatment, within 2 to 4 weeks, then every 3 to 4 months<\/li><li>(pediatrics) ALT and AST; at baseline and with modification of ARV treatment, then every 3 to 4 months or more frequently if signs of hepatotoxicity develop  consider increased ALT\/AST monitoring in patients with preexisting liver disease, liver enzyme abnormalities, or underlying hepatitis B or C, particularly during the first 3 month of therapy<\/li><li>(pediatrics 2 years or older) non-fasting lipid panel; at baseline and with modification of ARV treatment, then every 6 to 12 months; patients with lipid abnormalities should have a fasting lipid panel every 6 months or more frequently as clinically indicated<\/li><li>(pediatrics) urinalysis; at baseline, then every 6 to 12 months<\/li><li>(pediatrics, oral solution) serum osmolality and serum creatinine; in HIV-infected infants treated with ritonavir oral solution<\/li><li>(pediatrics, oral solution) signs and symptoms associated with alcohol and propylene glycol toxicity (eg, hyperosmolality, renal toxicity, CNS depression, seizures, hypotonia, ECG changes, hemolysis) with use of oral solution formulation in infants<\/li><\/ul>"},{"id":"923544-s-11","title":"How Supplied","mono":"<b>Norvir<\/b><br\/><ul><li>Oral Capsule, Liquid Filled: 100 MG<\/li><li>Oral Solution: 80 MG\/ML<\/li><li>Oral Tablet: 100 MG<\/li><\/ul>"},{"id":"923544-s-12","title":"Toxicology","sub":[{"id":"923544-s-12-31","title":"Clinical Effects","mono":"<b>AIDS ANTIVIRAL PROTEASE INHIBITORS<\/b><br\/>USES: Protease inhibitors are used in the treatment of HIV-1 infection. This class includes: atazanavir, darunavir, fosamprenavir calcium, indinavir sulfate, lopinavir\/ritonavir, nelfinavir mesylate, ritonavir, saquinavir mesylate, and tipranavir. PHARMACOLOGY: Protease inhibitors reversibly bind the HIV-1 protease necessary for protein cleavage and subsequent enzyme (reverse transcriptase, protease, and integrase) activation leading to inhibition of infectivity. TOXICOLOGY: Toxicological effects are generally an extension of adverse effects. EPIDEMIOLOGY: Overdose is uncommon and severe sequelae from acute overdose are rare. However, adverse effects and drug interactions are common. OVERDOSE: There are limited overdose data, despite more than 15 years of availability. In general, overdose effects seem to be well tolerated. The following effects have been reported: INDINAVIR: nausea, vomiting, abdominal pain, hematuria, crystalluria, renal insufficiency, and nephrolithiasis. RITONAVIR: vomiting, headache, and rash. ADVERSE EFFECTS: COMMON: Nausea, vomiting, diarrhea, peripheral neuropathy, and elevated liver enzymes are common. SEVERE: Severe effects include pancreatitis, liver failure, myelosuppression, heart block, and lactic acidosis. Other adverse effects specific to each drug include: ATAZANAVIR: hyperglycemia, hyperbilirubinemia (5%), nephrolithiasis, rash, nausea, vomiting, transaminitis, neutropenia (4%), hepatitis. DARUNAVIR: nausea, vomiting, lipodystrophy, transaminitis, hyperglycemia, rash, Stevens-Johnson syndrome (rare), hepatic failure (rare). FOSAMPRENAVIR: Transaminitis, hepatotoxicity (6%). INDINAVIR: Transaminitis, rash, nephrolithiasis (5%), hepatic steatosis (3%), lipodystrophy, and rarely, vasculitis, lactic acidosis, and rhabdomyolysis. LOPINAVIR\/RITONAVIR: hepatotoxicity, rash, hypercholesterolemia, nausea, vomiting, diarrhea. NELFINAVIR: transaminitis, hepatotoxicity (5%). RITONAVIR: nausea, vomiting, abdominal pain, paresthesias, hypercholesterolemia, hepatotoxicity, and rash, all of which are largely dose-dependent. SAQUINAVIR: nausea, vomiting, diarrhea, and abdominal pain are common. TIPRANAVIR: Transaminitis, hepatotoxicity (10%), rash, nausea, vomiting. DRUG INTERACTIONS: Drug interactions are common with this class of medications; most are mediated by Cytochrome P450 3A4. Drugs that are 3A4 inhibitors will decrease the metabolism of most protease inhibitors and increase toxicity. Administration of most protease inhibitors with drugs that are 3A4 substrates decreases metabolism and increases toxicity of these other drugs. Fosamprenavir, nelfinavir, ritonavir, saquinavir, atazanavir, and darunavir are all P450 3A4 substrates and inhibitors. Tipranavir, lopinavir\/ritonavir, and indinavir are P450 3A4 substrates only.<br\/>"},{"id":"923544-s-12-32","title":"Treatment","mono":"<b>AIDS ANTIVIRAL PROTEASE INHIBITORS<\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Supportive care remains the mainstay of care. Mild transaminitis can be monitored; discontinuation of therapy is usually not necessary. Therapy should be changed for persistently rising transaminases or evidence of hepatic synthetic dysfunction. Nausea and vomiting should be treated with antiemetics. Peripheral neuropathies are generally reversible with drug withdrawal and can be treated with pain management as needed. Mild elevations in lactic acid do not require discontinuation of therapy unless systemic acidemia ensues. MANAGEMENT OF SEVERE TOXICITY: Supportive care remains the mainstay of care in severe toxicity. Withdrawal of the offending agent is imperative to improvement in severe adverse reactions. Stevens-Johnson Syndrome should be treated with supportive care and consideration of corticosteroid and IV immunoglobulin therapy. Granulocyte colony stimulating factor (GCSF) should be considered for neutropenia complicated by infection felt to be secondary to protease inhibitors. Hepatic failure should prompt consultation with a transplant center.<\/li><li>Decontamination: PREHOSPITAL: No prehospital decontamination is indicated. Prehospital care should focus on assessment of vital signs and general supportive care. HOSPITAL: Activated charcoal may be considered for patients who present early after overdose if they are awake and willing to drink the charcoal. Gastric lavage is not indicated as overdose is not life-threatening.<\/li><li>Antidote: None<\/li><li>Monitoring of patient:  Obtain a basic metabolic panel, and monitor CBC and liver enzymes in symptomatic patients. Right upper quadrant ultrasound should be considered to evaluate for alternative etiologies of transaminitis.<\/li><li>Enhanced elimination procedure: Hemodialysis and whole bowel irrigation have no role in the management of protease inhibitor overdose.<\/li><li>Patient disposition: HOME CRITERIA: Suicidal patients should be referred to a healthcare facility. Asymptomatic patients with inadvertent ingestion of a protease inhibitor can be observed at home. OBSERVATION CRITERIA: Asymptomatic or mildly symptomatic patients should be observed for 4 to 6 hours, primarily monitoring signs of co-ingestant toxicity. ADMISSION CRITERIA: Patients with severe toxicity should be admitted. Patients with hepatic failure or severe acidosis should be admitted to an intensive care setting. CONSULT CRITERIA: Infectious disease should be consulted if a change to anti-retroviral therapy is indicated. Consult a medical toxicologist or poison center for patients with severe toxicity or in whom the diagnosis is unclear.<\/li><\/ul>"},{"id":"923544-s-12-33","title":"Range of Toxicity","mono":"<b>AIDS ANTIVIRAL PROTEASE INHIBITORS<\/b><br\/>TOXICITY: INDINAVIR: 52 out of 79 adults developed moderate toxicity after ingesting 2.8 to 48 g; most recovered rapidly. LOPINAVIR\/RITONAVIR: An adult developed vomiting, abdominal pain and headache after ingesting 54 g lopinavir and 13.5 g ritonavir as combination therapy; he recovered. RITONAVIR: An adult, who ingested 1500 mg\/day for 2 days, developed paresthesias which resolved with dose reduction. SAQUINAVIR: An ingestion of 8 g caused no toxicity, and 7200 mg\/day for 25 weeks was well tolerated. THERAPEUTIC DOSE: Varies by specific agent.<br\/>"}]},{"id":"923544-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to practice safe sex. Drug does not prevent disease transmission.<\/li><li>Drug may decrease effectiveness of estrogen-based hormonal contraceptives with concurrent use. Recommend additional non-hormonal form of birth control during therapy.<\/li><li>Drug may cause asthenia, circumoral and peripheral paresthesia, diarrhea, anorexia, nausea, taste perversion, abdominal pain, and vomiting.<\/li><li>Advise patient to report signs\/symptoms of pancreatitis, hepatitis, or PR prolongation (dizziness, light-headedness, abnormal heart rhythm, or loss of consciousness).<\/li><li>Tell patient to report signs\/symptoms of hyperglycemia, as drug has the potential to cause a new onset or exacerbation of diabetes.<\/li><li>Instruct patient to take drug with food, if possible.<\/li><li>Advise patient against sudden discontinuation of drug.<\/li><li>Tell patient there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><\/ul>"}]}